Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-14
2011-06-14
Weddington, Kevin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S178000, C514S396000, C514S866000, C514S909000
Reexamination Certificate
active
07960410
ABSTRACT:
The invention concerns the use of ketoconazole and derivatives having a corresponding biological activity, and combinations thereof, in the treatment of abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids.
REFERENCES:
patent: 4466978 (1984-08-01), Naylor
patent: 4491588 (1985-01-01), Rosenburg et al.
patent: 4814333 (1989-03-01), Ravaris
patent: 4871741 (1989-10-01), Gadebusch et al.
patent: 4956391 (1990-09-01), Sapse
patent: 5175144 (1992-12-01), Walser
patent: 5432176 (1995-07-01), Walser
patent: 5527788 (1996-06-01), Svec et al.
patent: 5591736 (1997-01-01), Walser
patent: 5849740 (1998-12-01), Marin
patent: 6040307 (2000-03-01), Gray et al.
patent: 6166017 (2000-12-01), Marin
patent: 6274582 (2001-08-01), Mårin
patent: 6428809 (2002-08-01), Abrams et al.
patent: 6545028 (2003-04-01), Jensen et al.
patent: 6642236 (2003-11-01), Marin
patent: 6702683 (2004-03-01), Abrams et al.
patent: 6846800 (2005-01-01), Johannsson et al.
patent: 6881739 (2005-04-01), Marin et al.
Balbi et al., “Treatment of Ketoconazole in diabetic patients with vaginal candidiasis”, Drugs Under Experimental and Clinical Research, vol. 12, No. 5, pp. 413-414 (1986), see enclosed abstract.
Reich et al., “Rhinocerebral mucormycosis in a diabetic ketoacidotic patient”, Jorunal of Neurology, vol. 232, No. 2, pp. 115-117 (1985).
Sonino et al., “Ketoconazole treatment in Cushing's syndrome: experience in 34 patients”, Clinical Endocrinology, vol. 35, No. 4, pp. 347-352 (Oct. 1991), see enclosed abstract.
Pepper, G.M. et al, “Ketoconazole Reversed Hyperandrogenism . . . ,” J. Clin. Endocrin. & Metab., 1987, vol. 65, No. 5, pp. 1047-1052.
Verhelst, J.A. et al., “Use of Ketoconazole in the Treatment of Virilizing Adrenocortical Carcinoma,” ACTA Endocrin., 1989, vol. 121, No. 2, pp. 229-234.
Sonino, N., et al., “Ketoconazole treatment in Cushing's syndrome . . . ,” Clin. Endocrin. 1991 United Kingdom, 1991, vol. 35, No. 4, pp. 347-352.
Krishnaiah, Y.S.R., et al., “Drug Interaction of tolbutamide with ketoconazole in diabetic rabbits,” Indian J. Pharmacol., 1993, vol. 125, No. 3, pp. 146-148.
Brindley, D.N., et al., “Neuroendocrine regulation and obesity,” Int'l J. Obesity 1992 United Kingdom, 1992, vol. 16, No. Suppl. 3, pp. S73-S79.
European Patent Office, European Search Report in respect of EP 03 01 2414, Aug. 4, 2003.
Paola Loli et al., “Use of Ketonconazole in the Treatment of Cushing's Syndrome,” J. Clin. Endocrinology and Metabolism, vol. 63, No. 6, 1365-1371.
G.M. Pepper, “Ketoconazole Reverses Hyperandrogenism in a Patient with Insulin Resistance and Acanthosis Nigricans”, J. Clin. Endo. & Metab., v. 66, No. 5, 1047-1052.
Viscera Obesity: A “Civilization Syndrome”. Obesity Research, vol. 1 No. 3, May 1993.
A.T. Sapse, “Stress, Cortisol, Interferon and ‘Stress’ Diseases —1. Cortisol as the Cause of ‘Stress’ Diseases”. Medical Hypotheses, vol. 13. pp. 31-44, 1984.
Bjorntorp, P., “Metabolic implications of body fat distribution,” Diabetes Care 1991, 14(12):1132-1143.
Bjorntorp, P., “Regional fat distribution—implications for type II diabetes,” Int J Obesity 1992, 16(4):S19-S27.
Brindley, D.N., “Role of glucocorticoids and fatty acids in the impairment of lipid metabolism,” Int J Obesity 1995, 19(1):S69-S75.
Byrd et al., “Paecilomyces varioti pneumonia in a patient with Diabetes Mellitus,” J. Diab Comp 1992, 6:150-153.
Nichols, R., “Problems associated with medical therapy of Canine Hyperandrenocorticism,” Problems in Veterinary Medicine, 1990, 2(4):551-556.
Peeke and Chrousos, “Hypercortisolism and obesity,” Ann. New York Acad. Sci. 665-676.
Rotstein et al., “Stereoisomers of ketoconazole: Preparation and biological activity,” J Med Chem 1992, 35:2818-2825.
A.T. Sapse, “Stress, Cortisol, Interferon and ‘Stress’ Diseases —I. Cortisol as the Cause of ‘Stress’ Diseases”. Medical Hypotheses, vol. 13. pp. 31-44, 1984.
Siever, L.J et al., “Plasma Cortisol Response to Clonidine in Depressed Patients and Controls” Arch Gen Psychiatry, Jan. 1984, p. 63-68, vol. 41.
Phillips, P., et al.; “Adrenal Response to Corticotropin during Therapy with Itraconazole,” Antimicrobial Agents and Chemotherapy, Apr. 1987, pp. 647-649.
Voet, D. and J. Voet, Biochemistry, 2nd Ed., 1995, Fig. 23-52 (Sect. 23-6), John Wiley & Sons, Inc. (New York).
Rang, H., et al., Pharmacology, 1995, pp. 421-422, Churchill Livingstone (New York).
Cortendo AB
Ruben Bradley N.
Weddington Kevin
LandOfFree
Method for treating insulin resistance, abdominal obesity,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating insulin resistance, abdominal obesity,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating insulin resistance, abdominal obesity,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2701301